ANZCTR search results

This study aims to evaluate the uptake, engagement and short-term effects of an online parenting program 'Partners in Parenting Kids' (PiP Kids). The online program is designed for parents/caregivers of children aged between 5-11 years and is comprised of up to 12 online self guided educational modules empowering parents/caregivers to support their child to prevent or reduce symptoms of depression and anxiety. Before commencing the program, participants will be able to select between a ‘Tailored’ pathway to their program (i.e. program content is personalised based on responses to an initial self assessment) or a ‘Non-tailored’ pathway (i.e. program content is completely self selected with no self assessment completed) . The project aims to evaluate the PiP Kids program for its: (1) uptake and engagement via the Raising Children Network (RCN) website (2) effects on preventive parenting practices, parental self-efficacy and child internalising symptoms (3) parent/caregiver program satisfaction (4) ability to meet parent/caregiver initial pre-program goals We also aim to explore parent/caregivers’ qualitative feedback about their experiences of PiP Kids through qualitative feedback interviews conducted at the post-program timepoint. No hypotheses are specified for this aim. For Aims (1) to (4), it is hypothesised that from pre to post program (90 days later) users who complete the PiP Kids program will report: (1) improved (higher) scores on the The Parenting to Reduce Child Anxiety and Depression Scale (PaRCADS), indicating improvements in preventive parenting practices; (2) improved (higher) scores on the Parental Self-Efficacy Scale-Child (PSES-C), indicating increased parental self-efficacy in parenting domains associated with child depression and anxiety; (3) reduced scores on the parent-report version of the Paediatric Symptoms Checklist (PSC-17) internalising subscale, indicating reduced internalising symptoms in their child; (4) the program to be satisfactory and meeting their initial pre-program goals

More than half the people living in Australia do not exercise regularly, an issue even more acute for adults with physical disabilities (PwD). Physical disabilities can affects motor control, skill, and coordination. There is an association between the severity of a disability and the presence of additional health and psychosocial issues leading to greater complexity of the condition. PwD find it difficult achieving the recommended amounts of physical activity. PwD have often excluded from research, particularly studies relating to exercise. Most PwD research has focused on children and young adolescents with less complex disabilites and who live in metropolitan areas. It is often hard for people with disabilities to exercise because of difficulties accessing places where there are opportunities to be active. In addition, they might not have the right support. The All-Abilites program has been modelled on FitSkills, which was was created to address this issue. FitSkills matches people with disabilities and health students (Nursing, Occupational Therapy, Exercise Science) to exercise together in a gym environment. Studies have shown that FitSkills can engage youth with disabilities in community-based exercise, a finding further supported by a mixed-method case study recently completed (unpublished) carried out in a regional area. With additional support, including screening, risk assessment, and additional professional support for the peer-mentor health student, FitSkills can be tailored for young people with complex disabilities. Our project examines how well FitSkills, renamed All-Abilities, can be implemented in a real-world setting for PwD who live regionally. In this study, we want to see if we can implement an intervention that has the potential to help PwD living regionally to improve their health, well-being, and ability to participate in activities that are meaningful to them.

This prospective randomized controlled study of patients who are successfully resuscitated following cardiac arrest patients will receive either MeB or placebo, in addition to standard medical care. The study will assess the impact of MeB on overall survival, neurological outcomes, and hemodynamics. We hypothesise that MeB will be safe and effective in improving markers of neuronal injury, with a possible translation to improved mortality. The findings will inform future large-scale research aimed at improving outcomes in this currently highly morbid condition.

This study aims to assess the safety and effectiveness of a specialised treatment called basivertebral nerve ablation (BVNA) for people with ongoing low back pain coming from changes in the bones of the spine (called Modic changes). This study also aims to assess the effectiveness of BVNA in other conditions which haven't been reported in the literature. We hypothesise that BVNA may provide extended benefits to patients outside of its proven clinical indications.

This study aims to co-design BCT intervention to support smoking and vaping cessation that is easy to use, acceptable, and tailored to the needs of mental health consumers.

This is an investigational combination treatment arm within the ALLG AMLM26 INTERCEPT trial platform, which is registered on ANZCTR with ID ACTRN12621000439842. This treatment arm (PHI-101) will be evaluated for its activity in a population of participants with progressive acute myeloid leukemia (AML). Who is it for? You may be eligible for to receive this treatment if you are a part of the AMLM26 Intercept trial which is registered on ANZCTR with ID ACTRN12621000439842 (ie if you are aged 18 or older, you have been diagnosed with progressive acute myeloid leukemia, and are currently in your first or second morphologic remission with a known and trackable minimal residual disease (MRD) marker.). If you are on the AMLM26 Intercept trial you may be eligible for this treatment option if your disease is worsening. The trial management committee will review your disease characteristics and determine your best treatment option(s) available on the trial. Study details PHI-101 will be given orally at a dose of 160 mg on an empty stomach. It should be administered at least two hours after a meal, preferably following an overnight fast. After taking PHI-101, you must continue fasting for an additional two hours.PHI-101 will be administered on days 1-28 (every day) of each 28-day cycle. Participants will undergo a disease assessment at screening after cycle 1, cycle 2, cycle 3, cycle 6, cycle 8, cycle 10, cycle 12 and then 2 monthly until progression. This will require blood tests and bone marrow biopsies. Safety and tolerability of treatment will be assessed throughout the trial whilst you are receiving treatment. Health related quality of life during treatment will be assessed on the first treatment day of 3 consecutive cycles. This study is being carried out to improve the way we treat cancer patients who may have limited treatment options available to them. It is hoped that PHI-101 will be well tolerated and may improve outcomes for future patients, however, there may be no clear benefit from participation in this study.

This study aims to evaluate digital health promotion resources targeting Australians aged in their 50s, 60s and 70s who engage in risky alcohol consumption. Traditional messaging about long-term alcohol-related disease risks can often fail to resonate with this group. To address this, this project has developed short videos based on what this demographic has told us they want: real stories and real people that model positive changes in alcohol use. The intervention seeks to empower individuals with alternative social and relaxation strategies to support healthy ageing, while also shifting attitudes, norms, and knowledge toward lower-risk drinking behaviours.

Abdominal bloating/distension is a common and often debilitating condition that affects patients with Disorders of the Gut-Brain Interaction (DGBI). There are very few effective treatments. We believe that bloating and distension of the abdomen is caused by an abnormal response from the abdominal muscles causing them to relax and protrude. Electrical Muscle Stimulation (EMS) is a non-invasive, commercially available technology that is often used by physiotherapists, sports physicians and athletes. EMS devices can also be purchased and used in the home for various indications. Like an electrocardiogram (ECG) or ‘heart trace’, the EMS device is connected to the abdominal skin via gel pads (electrodes). This study will evaluate whether EMS to the abdominal muscles can improve symptoms of chronic abdominal bloating through activation of the abdominal muscles in response to meals. The outcomes of this study will guide future research and inform clinical management strategies for functional gastrointestinal disorders. We believe that EMS applied to the abdomen can improve symptoms of abdominal distension in people with chronic abdominal bloating/distension.

Current dietary advice for individuals with an ileoanal pouch is based on general healthy eating guidelines, rather than tailored recommendations. However, people respond to food differently, and it may not be appropriate to recommend the same dietary advice to everyone with a pouch. Our group is conducting a two-phase study to develop more personalised dietary recommendations. Phase 1 (Trial ID: ACTRN12624000912583) involved a lab-based investigation using fresh stool samples to assess how gut microbes break down specific food components. This registration refers to Phase 2, where the same participants will follow two different 7-day diets in a randomised crossover design. Stool samples collected after each diet will be tested using the same in vitro assay developed in Phase 1. The goal is to determine whether the assay can detect meaningful differences in microbial fermentation based on dietary intake. We believe people with an ileoanal pouch respond differently to different diets, and that our lab test can pick up these differences. This could help us move away from one-size-fits-all advice and towards personalised fibre recommendations.

This project aims to understand how certain factors like age and PCOS impact the endometrium by using menstrual fluid. Like all tissues in the body, the endometrium also changes over time. In Australia, more women are getting pregnant for the first time later in life. However, as we age, fertility naturally declines and the endometrium changes as well. As the endometrium plays a key role in pregnancy, we want to understand how aging affects it and the impacts this may have. Similarly, people who have been diagnosed with PCOS, typically have longer, irregular menstrual cycles. We think this could impact the endometrium in a similar way to aging. We will assess markers of ageing in endometrial cells isolated from menstrual fluid. This research is important because if the endometrium isn’t functioning properly, it can impact fertility, regular menstruation and reproductive health overall.